Inosine 5'‐Monophosphate to Raise Serum Uric Acid Level in Multiple System Atrophy (IMPROVE‐MSA study). Issue 5 (30th November 2020)

• Record Type: Journal Article
• Authors: Jung Lee, Jae; Han Yoon, Jung; Jin Kim, Sang; Soo Yoo, Han; Jong Chung, Seok; Hyun Lee, Yang; Yun Kang, Suk; Shin, Hae‐Won; Keun Song, Sook; Yong Hong, Jin; Sunwoo, MunKyung; Eun Lee, Ji; Sam Baik, Jong; Sohn, Young H.; Hyu Lee, Phil
• Is Part Of: Clinical pharmacology & therapeutics. Volume 109:Issue 5(2021)
• Page Start: 1274
• Page End: 1281
• Publication Date: 2020-11-30
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2082
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : The aim of this trial was to investigate the safety, tolerability, and capability of serum uric acid (UA) elevation of inosine 5'‐monophosphate (IMP) in multiple system atrophy (MSA). The IMPROVE‐MSA trial was a randomized, double‐blind, placebo‐controlled trial in patients with MSA with no history of hyperuricemia‐related disorders. The participants were assigned to placebo ( n = 25) or IMP ( n = 30) in a 1 to 1 ratio, and then followed up for 24 weeks. The primary end points included safety, tolerability, and alteration of the serum UA level during the follow‐up period. The secondary end points were changes in scores of the unified MSA rating scale (UMSARS) and the Mini‐Mental Status Examination (MMSE) and Montreal Cognitive Assessment (MoCA). The total number of adverse events (AEs) and serious AEs was comparable between the active and placebo groups. Serum UA level (mg/dL) was significantly increased from baseline (active vs. placebo, 4.57 vs. 4.58; P = 0.98) to study end point (6.96 vs. 4.43; P < 0.001) in the active group compared with the placebo group (time × group interaction; P < 0.001). The change in UMSARS scores did not differ between the active and placebo groups. However, the active group showed better alterations in MoCA scores with nominal significance ( P < 0.001) and tendency for better alterations in MMSE scores ( P = 0.09) than the placebo group. Our data demonstrated that IMP treatment was generally safe and well‐tolerated in patients with MSA. A further trial with a long‐term follow‐up is required to examine whether UA elevation will slow clinical progression in early MSA.